3-O-methyldopa administration does not alter fluorodopa transport into the brain.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
3-O-methyldopa administration does not alter fluorodopa transport into the brain. / Guttman, M; Léger, G; Cedarbaum, J M; Reches, A; Woodward, W; Evans, A; Diksic, M; Gjedde, A.
In: Annals of Neurology, Vol. 31, No. 6, 1992, p. 638-43.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - 3-O-methyldopa administration does not alter fluorodopa transport into the brain.
AU - Guttman, M
AU - Léger, G
AU - Cedarbaum, J M
AU - Reches, A
AU - Woodward, W
AU - Evans, A
AU - Diksic, M
AU - Gjedde, A
PY - 1992
Y1 - 1992
N2 - To determine if 3-O-methyldopa (3OMD) significantly inhibits the transport of 6-[18F]fluorodopa (6-FD) into the brain at the concentration normally encountered during L-dopa administration, we performed 6-FD studies with positron emission tomography in cynomolgus monkeys in the presence and absence of 3OMD. Infusion of 3OMD was designed to produce plasma concentrations equivalent to those seen in patients on chronic L-dopa therapy. Plasma 3OMD levels of 39 +/- 4 microM did not alter the blood-brain transfer rate of 6-FD. 6-FD positron emission tomographic studies in parkinsonian patients will therefore not be altered by 3OMD present in the blood in those patients taking L-dopa preparations. These results do not support the hypothesis that transport of L-dopa into the brain is inhibited by 3OMD to cause the declining response seen in patients with advanced Parkinson's disease.
AB - To determine if 3-O-methyldopa (3OMD) significantly inhibits the transport of 6-[18F]fluorodopa (6-FD) into the brain at the concentration normally encountered during L-dopa administration, we performed 6-FD studies with positron emission tomography in cynomolgus monkeys in the presence and absence of 3OMD. Infusion of 3OMD was designed to produce plasma concentrations equivalent to those seen in patients on chronic L-dopa therapy. Plasma 3OMD levels of 39 +/- 4 microM did not alter the blood-brain transfer rate of 6-FD. 6-FD positron emission tomographic studies in parkinsonian patients will therefore not be altered by 3OMD present in the blood in those patients taking L-dopa preparations. These results do not support the hypothesis that transport of L-dopa into the brain is inhibited by 3OMD to cause the declining response seen in patients with advanced Parkinson's disease.
U2 - 10.1002/ana.410310611
DO - 10.1002/ana.410310611
M3 - Journal article
C2 - 1514775
VL - 31
SP - 638
EP - 643
JO - Annals of Neurology
JF - Annals of Neurology
SN - 0364-5134
IS - 6
ER -
ID: 14944932